[artículo] 
inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 423-427

Título :	Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial
Tipo de documento:	texto impreso
Autores:	William J. Burke, Autor ; Shelton E. Hendricks, Autor ; Delores McArthur Miller, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 423-427
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Antidepresivos de segunda generación, Trastorno depresivo, Fluoxetina.
Resumen:	Fluoxetine (FLX) has a unique pharmacokinetic profile. Its major metabolite, norfluoxetine (NFLX), possesses FLX's antidepressant efficacy and a half-life of 7 to 15 days, suggesting the possibility of nonstandard dosing strategies. This study examined the tolerability of a weekly dose and its equivalence to daily dosing of FLX for the continuation phase of treatment for major depressive disorder (MDD).
Link:	./index.php?lvl=notice_display&id=31178

[artículo] Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial [texto impreso] / William J. Burke, Autor ; Shelton E. Hendricks, Autor ; Delores McArthur Miller, Autor . - 2023 . - pp. 423-427.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 423-427

Palabras clave:	Antidepresivos de segunda generación, Trastorno depresivo, Fluoxetina.
Resumen:	Fluoxetine (FLX) has a unique pharmacokinetic profile. Its major metabolite, norfluoxetine (NFLX), possesses FLX's antidepressant efficacy and a half-life of 7 to 15 days, suggesting the possibility of nonstandard dosing strategies. This study examined the tolerability of a weekly dose and its equivalence to daily dosing of FLX for the continuation phase of treatment for major depressive disorder (MDD).
Link:	./index.php?lvl=notice_display&id=31178